The influence of naloxone infusion on opioid side effects during epidural fentanyl with patient-controlled analgesia
Gen-Lin JI,Jin ZHANG,Heng-Xing ZHENG,Liang LIANG,Ying-Min ZHANG,Min ZHANG,Li-Ze XIONG
DOI: https://doi.org/10.3321/j.issn:1000-2790.2000.04.030
2000-01-01
Abstract:AIM The purpose of this study was to assess the influence of the two doses of naloxone for the prevention of opioid related side effects in patients receiving patient controlled epidural analgesia. METHODS 150 patients classified as ASA status Ⅰ~Ⅲ who were scheduled for total abdominal hysterectomy under combined spinal and epidural anesthesia (CSE) were enrolled in this study. 1 h after the operation, all patients received 4 mg·L -1 fentanyl, 0.5 g·L -1 bupivacaine and 2 mg·L -1 adrenarine as PCEA. The patients were randomized into three groups to receive either saline(A), 4 mg·L -1 (B) naloxone and 6 mg·L -1 (C) naloxone. Visual analog scores (VAS), the incidence and scores of postoperative nausea, vomiting, pruritus, sedation and consumption of fentanyl and naloxone during the 24 h study were recorded. Blood pressure, respiratory rate, and oxyhemoglobin saturation were also monitored. RESULTS The fentanyl infusion rate in the three groups was about 0.3 μg·kg -1 ·h -1 and naloxone infusion rate in Group B and C was (0.3±0.12)μg·kg -1 ·h -1 and (0.45±0.19)μg·kg -1 ·h -1 , respectively, which were equally effective in reducing the incidence and the scores of nausea, vomiting, and pruritus compared with placebo( P 0.05), There were no difference in the visual analog scores for pain and sedation among the three groups. The total consumption of fentanyl was a little lower in the two noloxone groups compared with that of placebo at 24 h postoperatively. CONCLUSION Patients received fentanyl and bupivacaine mixture as PCEA are effectively relived of postoperative pain and the adding of naloxone (0.3~0.45 μg·kg -1 ·h -1 ) not only ensures the good quality of analgesia, but also attenuates the side effects, and appears to reduce the postoperative opioid requirements.